NaCl 0.9%: Clinical Trials

11 trials of NaCl 0.9%, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 2 terminated, 1 unknown. 11 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 111Completed 8, Terminated 2, Unknown 1
Phase 26Completed 3, Terminated 2, Unknown 1

Follow NaCl 0.9%: new trials by email Literature Review of NaCl 0.9% trials Research Report on NaCl 0.9%

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combined Antioxidant Therapy Against Myocardial Reperfusion Injury. Phase I Study.
Antioxidant therapy, NaCl 0.9% - Acute Myocardial Infarction, Ischemia-reperfusion Injury
Phase 1CompletedUniversity of Chile182022-08-092024-01-12
HAT for the Treatment of Sepsis Associated With NASTI
HAT, Placebo - Necrotizing Soft Tissue Infection, Sepsis
Phase 1 / Phase 2TerminatedAscension Health102021-09-102024-07-24
Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS
Umbilical cord Wharton's jelly-derived human, NaCl 0.9% - Severe Acute Respiratory Syndrome Coronavirus 2, Severe Acute Respiratory Distress Syndrome
Phase 1 / Phase 2CompletedAssistance Publique - Hôpitaux de Paris472020-04-062022-02-18
Cardiac Safety Evaluation of P03277
P03277 0.1 mmol/kg, Moxifloxacin 400mg, NaCl 0.9% - Healthy Volunteers
Phase 1CompletedGuerbet482017-08-212022-07-18
FEIBA and Use of Blood Products in Cardiac Surgery
FEIBA, Normal Saline - Cardiovascular Disease
Phase 1CompletedOregon Health and Science University122016-02-012020-07-14
Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)
Iron infusion, Normal saline infusion - Postural Orthostatic Tachycardia Syndrome
Phase 1 / Phase 2TerminatedMayo Clinic32014-12-172017-11-17
Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions
P03277, Placebo - Healthy Volunteers, Brain Lesion
Phase 1 / Phase 2CompletedGuerbet1422013-11-252021-05-14
Brain Ketone Metabolism in Type 1 Diabetes
Beta-hydroxybutyrate, Normal Saline - Type 1 Diabetes, Hypoglycemia
Phase 1CompletedYale University442013-05-142023-04-27
A Proof of Concept Study to Determine the Local Delivery and Efficacy of Nanocort
Nanocort, Methylprednisolone, Placebo - Atherosclerosis
Phase 1 / Phase 2UnknownAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)212012-05-012012-07-23
Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers
treprostinil, iloprost, NaCl 0.9% - Healthy
Phase 1 / Phase 2CompletedUniversity Hospital, Grenoble202010-01-012011-10-06
Placebo-Controlled Crossover Study for the Investigation of the Effect of Pantoprazole on Cardiac Contractility
Pantoprazole, Placebo - Healthy
Phase 1CompletedHerzzentrum Goettingen202005-05-012009-03-24

Conditions studied

Atherosclerosis (1)  ·  COVID-19 (1)  ·  Cardiovascular Diseases (1)  ·  Diabetes Mellitus, Type 1 (1)  ·  Hypoglycemia (1)  ·  Myocardial Reperfusion Injury (1)  ·  Postural Orthostatic Tachycardia Syndrome (1)  ·  Reperfusion Injury (1)  ·  Respiratory Distress Syndrome (1)  ·  Sepsis (1)

Sponsors

Guerbet (2)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)  ·  Ascension Health (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Herzzentrum Goettingen (1)  ·  Mayo Clinic (1)  ·  Oregon Health and Science University (1)  ·  University Hospital, Grenoble (1)  ·  University of Chile (1)  ·  Yale University (1)

Countries

United States (4)  ·  Belgium (2)  ·  France (2)  ·  Chile (1)  ·  Germany (1)  ·  Netherlands (1)

Top investigators

Abraham IJ Gajardo, MD, PhD (1)  ·  Amie Jones, MD (1)  ·  E S Stroes, MD PhD (1)  ·  Frederic Vanhoutte, MD (1)  ·  Gerd Hasenfuss, Prof. Dr. (1)  ·  Raimund Herzog, MD (1)  ·  Thomas Resch, M.D. (1)  ·  Wouter Haazen, MD (1)

Results publications

PMID 19301059, PMID 23400744, PMID 30870257, PMID 34215339, PMID 34774107, PMID 35189925, PMID 38973337

NIH funding

2004 (1), 2009 (1), R01DK101984 (1)